Allogene Therapeutics Profit Margin

The latest profit margin for ALLO is -Infinity% as of March 2026. That compares with 11469.23% in the prior-year period — down Infinity% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside Allogene Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALLO's profit margin moved from 11469.23% to -Infinity% — a Infinity% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allogene Therapeutics's valuation or profitability profile.

Against Healthcare companies, ALLO currently prints -Infinity% for profit margin, while the sector average sits near 15.52%. That is roughly Infinity% below the sector mean. Large gaps often invite a closer look at Allogene Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Allogene Therapeutics converts resources into returns. At -Infinity%, ALLO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 11469.23% in the prior-year period — down Infinity% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALLO's profit margin (-Infinity%), review year-over-year change from 11469.23%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.